William Baumbach

Dr. Baumbach, Ph.D. has served as Vice President, Scientific Affairs for Orchestra BioMed’s Focal Therapies development group since May 2018. He has over 30 years of experience in pharmaceutical, biotechnology, and medical device R&D.

He co-founded Caliber Therapeutics and has served as its Chief Scientific Officer since 2008. Prior to Caliber, he was the Vice President of Research & Development at X-Cell Medical, a Drug-Eluting Stent startup that was based on a novel therapeutic agent, beta estradiol, that offered an enhanced safety profile. Dr. Baumbach oversaw development through a randomized first-in-human clinical trial. Prior to X-Cell, he was Director of Biology at Morphochem, a trans-Atlantic chemical genomics biotech company with pre-clinical product candidates in oncology, diabetes, and anti-thrombosis from June 2000 until August 2002. From 1984 to 2000, Dr. Baumbach held a number of positions with the Molecular/Genetic Screen Design group at Wyeth Pharmaceuticals (AHP), including as Principal Research Scientist. Dr. Baumbach has over 13 years of experience in pharmaceutical research, mainly in the areas of peptide hormone receptors, GPCRs, and neurotransmitter transporters. Dr. Baumbach has published over 30 peer-reviewed articles, is an inventor on 8 issued patents, and served on the editorial board of Endocrinology, and as an adjunct professor at Rutgers. He received his Bachelor's, Masters and Ph.D. degrees in Biochemistry and Molecular Biology from Princeton University.